Guardant Health and AstraZeneca entered into a multiyear agreement that will allow them to jointly develop blood-based companion diagnostic assays to determine non-small cell lung cancer patients' response to Tagrisso, or osimertinib.
Eloctate, or coagulation factor [(recombinant), Fc fusion protein], was associated with improvements in annualized bleeding rates over four years, as was Alprolix, or coagulation factor IX [(recombinant), Fc fusion protein]. Eloctate is indicated for the treatment of hemophilia A; Alprolix is indicated for the treatment of hemophilia B. The findings come from two extension studies and were presented at the American Society of Hematology's annual meeting.
Australia's Therapeutic Goods Administration has approved Aplidin, or plitidepsin, combined with dexamethasone, to treat patients with relapsed/refractory multiple myeloma. PharmaMar and Specialised Therapeutics Asia have a licensing deal to commercialize Aplidin in Australia, New Zealand and a dozen Asian nations.
A review in the journal Arthritis Research & Therapy found that systemic lupus erythematosus is associated with increased risk of 16 types of cancer, including some hematopoietic and lymphatic cancers. The analysis of data from 24 studies indicated a higher risk for non-Hodgkin lymphoma, Hodgkin lymphoma, leukemia and multiple myeloma.
A $300 million manufacturing and research and development facility has been opened by Siemens Healthineers at its East Walpole campus in Massachusetts. The facility, which will manufacture laboratory diagnostic devices, has created over 275 jobs as of December and is expected to employ 700 new workers by 2026.
Grail -- a Menlo Park, Calif.-based cancer testing startup backed by high-profile investors, including Amazon founder Jeff Bezos and Microsoft co-founder Bill Gates -- could launch an initial public offering in the US as early as next year, depending on stock market conditions, sources say. Grail is developing a test for early detection of a wide range of cancers and had considered a Hong Kong listing.
Patients with severe hepatic steatosis who also had thrombocytopenia were found to be at a higher risk for cardiovascular-related mortalities and all-cause mortality. The abstract was presented at the American Association for the Study of Liver Diseases' 2018 Liver Meeting.
Correctly distinguishing in vitro from in vivo hemolysis is clinically important because the latter could be a sign of various pathological conditions, including some that could be life-threatening if untreated, writes John Mitsios, assistant director of the special coagulation laboratory at BioReference Laboratories. In vivo hemolysis can be caused by several factors including blood cell defects, or autoimmune hemolytic anemia and hemolysis after an incompatible transfusion. In vitro hemolysis usually results from pre-analytical factors such as blood drawing and specimen handling.
- Page 1